Verily, a leading company in precision health technology under the Alphabet umbrella, and OneOncology, a prominent national platform supporting independent oncology practices, have joined forces in a strategic partnership aimed at optimizing the efficiency of clinical trials.

Under this collaboration, Verily will seamlessly integrate its innovative clinical trial management software (CTMS) platform, SignalPath, into the practices operating within the OneOncology Research Network, referred to as OneR. This integration of SignalPath will empower participating sites to bolster their operational infrastructure, streamline regulatory procedures, and foster closer collaboration with research sponsors.

Dr. Davey Daniel, Chief Medical Officer at OneOncology, highlighted the intrinsic importance of clinical trial research in top-tier cancer care programs. Dr. Daniel stated, "Leveraging technology to create a comprehensive platform within OneR allows us to elevate the clinical trial programs of our partners. This, in turn, not only promotes wider access to clinical trials but also advances health equity."

Distinguished by its utilization of cutting-edge protocol digitization technology, SignalPath stands out as the sole CTMS that systematically configures study protocol workflows within the platform. This dynamic approach translates to substantial time and effort savings for site personnel. Moreover, SignalPath has been purposefully designed to mitigate the financial complexities and temporal challenges associated with conducting clinical studies, all the while prioritizing study quality and the allocation of time to patient care.

Dr. Brad Hirsch, Head of Product & Implementation at Verily and co-founder of SignalPath, emphasized the joint commitment of Verily and OneOncology to revolutionize the research experience for oncology practices by harnessing the potential of data and technology. Dr. Hirsch affirmed that SignalPath effectively realizes this objective by simplifying the workflows for oncologists and their teams, thereby allowing them to channel their focus towards delivering exceptional patient care.

The overarching goal of this strategic partnership centers on the expansion of research opportunities within community-based oncology centers. Through this expansion, the initiative seeks to enhance access to and participation in clinical trials for innovative cancer treatments. Despite a pipeline boasting over 1,300 potential anticancer drugs, a mere 6% of adult cancer patients in the U.S. engage in clinical trials.

OneOncology's ongoing collaboration with Verily is set to encompass the development of integrated solutions spanning their research and care product portfolios. This includes the creation of an oncology-centric longitudinal registry dedicated to propelling advancements in cancer research.
 

Source: businesswire.com

Report Abuse